Polygalasaponin F

Synonyms: 瓜子金皂苷己
Polygalasaponin F 是一种具有口服活性的三萜皂苷单体,可下调 Bax、p53、caspase-3、NF-κB p65 及 MEK1 的表达,恢复并上调 Bcl-2 的表达,激活 PI3K/Akt 信号通路,抑制 p38 MAPK 磷酸化、NF-κB 核转位、TLR4 介导的信号通路、线粒体自噬 (Mitophagy) 及 ROS 生成,从而提升细胞活力并抑制细胞凋亡 (Apoptosis),同时可维持线粒体功能、减轻 Ca2+ 超载、上调 pCREB 和 BDNF、维持细胞活力并抑制炎性细胞因子释放,还可缓解甲型流感 H1N1 诱导的肺损伤及脑缺血再灌注损伤,因此可用于帕金森病、脑缺血、甲型流感 H1N1 诱导的肺炎、脑卒中及阿尔茨海默病的相关研究。
产品编号: MS-U16168 纯度: 99.85% CAS No.: 882664-74-6 分子式: C53H86O23 分子量: 1091.24
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

Polygalasaponin F 是一种具有口服活性的三萜皂苷单体,可下调 Bax、p53、caspase-3、NF-κB p65 及 MEK1 的表达,恢复并上调 Bcl-2 的表达,激活 PI3K/Akt 信号通路,抑制 p38 MAPK 磷酸化、NF-κB 核转位、TLR4 介导的信号通路、线粒体自噬 (Mitophagy) 及 ROS 生成,从而提升细胞活力并抑制细胞凋亡 (Apoptosis),同时可维持线粒体功能、减轻 Ca2+ 超载、上调 pCREB 和 BDNF、维持细胞活力并抑制炎性细胞因子释放,还可缓解甲型流感 H1N1 诱导的肺损伤及脑缺血再灌注损伤,因此可用于帕金森病、脑缺血、甲型流感 H1N1 诱导的肺炎、脑卒中及阿尔茨海默病的相关研究。

生物实验数据

生物活性 Polygalasaponin F is an orally active triterpenoid saponin monomer that downregulates the expression of Bax, p53, caspase-3, NF-κB p65, and MEK1, restores and upregulates Bcl-2 expression, activates the PI3K/Akt signaling pathway, and inhibits p38 MAPK phosphorylation, NF-κB nuclear translocation, TLR4-mediated signaling, mitophagy, and ROS production, thereby enhancing cell viability and inhibiting apoptosis, while also maintaining mitochondrial function, alleviating Ca2+ overload, upregulating pCREB and BDNF, maintaining cell viability, and suppressing inflammatory cytokine release; it additionally alleviates influenza A H1N1-induced lung injury and cerebral ischemia-reperfusion injury, and can therefore be used in research related to Parkinson's disease, cerebral ischemia, influenza A H1N1-induced pneumonia, stroke, and Alzheimer's disease.
IC50 & Target

TLR4

 

PI3K

 

NF-κB

 

体外研究
(In Vitro)

Polygalasaponin F (0.1-10.0 μM; 24-48 h) 提高 Rotenone (MS-D42728) 损伤 PC12 细胞的存活率,降低细胞凋亡,抑制细胞中 ROS 的产生,保护细胞的线粒体膜电位,逆转细胞 ATP 耗竭,抑制细胞色素 c 从线粒体向细胞胞质的释放,调控细胞中凋亡蛋白的表达,降低 p53 水平、使 Bax/Bcl-2 比值恢复正常,并抑制 caspase-3 的激活。
Polygalasaponin F (0.1-10 μM) 可显著提升经氧糖剥夺/复氧 (OGD/R) 处理的 PC12 细胞、原代大鼠皮质神经元活力,上调细胞中 Bcl-2/Bax 的比值。
Polygalasaponin F (0.1-10 μM) 下调 OGD/R 处理的原代大鼠皮质神经元中活化 caspase-3 的表达,降低细胞凋亡水平。
Polygalasaponin F (1-10 μM) 可激活经 OGD/R 处理的 PC12 细胞中的 PI3K/Akt 信号通路。
Polygalasaponin F (0.1-10 μM; 1 h 预处理, 24 h LPS 孵育) 可剂量依赖性地抑制 LPS (MS-X54539) 诱导的 BV-2 小胶质细胞中 TNF-α 的分泌,抑制细胞中 NO、iNOS 蛋白的生成,抑制 p38 MAPK 磷酸化,提升细胞存活率。
Polygalasaponin F (0.1-10 μM; 1 h pretreatment, 24 h LPS co-incubation) 可通过减少 p65 核转位、增加胞质 p65 和 IkB-α 水平,以剂量依赖的方式抑制 LPS 诱导的 BV-2 小胶质细胞中 NF-κB 激活。
Polygalasaponin F (10-5 M; 24 h) 可通过 PI3K/AKT 依赖的机制抑制 LPS 诱导的 BV-2 小胶质细胞中 NF-κB p65 亚基的核转位,降低细胞中 AKT 的磷酸化水平。
Polygalasaponin F 可通过抑制一氧化氮和前列腺素 E2 的生成、降低促炎细胞因子 mRNA 的表达水平以及抑制 NF-κB 通路的激活,在 LPS 刺激的 RAW264.7 巨噬细胞和 BV2 小胶质细胞中发挥抗炎作用。
Polygalasaponin F (2-10 μM; 30 min pre-incubation then 24 h with 100 μM glutamate) 可浓度依赖性地提升经谷氨酸诱导细胞毒性处理的原代培养大鼠胚胎海马神经元的存活率。
Polygalasaponin F (10 μM; 24 h co-treatment with 100 μM glutamate) 可抑制谷氨酸诱导的原代培养大鼠胚胎海马神经元凋亡,提高 caspase-3 阳性细胞计数。
Polygalasaponin F (10 μM; 4 h co-treatment with 100 μM glutamate) 可通过阻断细胞外 Ca2+ 内流,抑制谷氨酸诱导的原代培养大鼠胚胎海马神经元内的 Ca2+超载。
Polygalasaponin F (10 μM) 可部分阻断原代培养的大鼠胚胎海马神经元中由 NMDAR 介导的电流,使电流幅度抑制 47.7%,逆转神经元中谷氨酸诱导的 NMDAR 亚基表达失调,使 NR2A 和 NR2B 水平恢复至接近对照组的水平,逆转神经元中 pCREB 和 BDNF 表达下调。
Polygalasaponin F (40 μM; 6 h) 可通过减轻氧化应激、维持线粒体功能、抑制过度线粒体自噬及减弱细胞凋亡,保护 HT22 小鼠海马神经元免受 OGD/R 损伤。

Cell Viability Assay

Cell Line: PC12 cells
Concentration: 0, 0.1, 1, 10.0 μM
Incubation Time: 48 h
Result: Increased the viability of rotenone-treated PC12 cells to 68.34%, 77.25%, and 84.91% (relative to control), respectively, in a dose-dependent manner.

Apoptosis Analysis

Cell Line: PC12 cells
Concentration: 0, 0.1, 1, 10.0 μM
Incubation Time: 24 h
Result: Decreased the rotenone-induced apoptosis rate of PC12 cells to 33.45%, 28.99%, and 20.59%, respectively, in a dose-dependent manner.

Western Blot Analysis

Cell Line: PC12 cells
Concentration: 0, 0.1, 1, 10.0 μM
Incubation Time: 24 h
Result: Dose-dependently blocked rotenone-induced cytochrome c release into the cytosol, reducing the relative intensity of cytosolic cytochrome c (normalized to β-actin) to levels significantly lower than rotenone-only treated cells.\nDose-dependently decreased rotenone-induced p53 overexpression, reduced the Bax/Bcl-2 ratio, and attenuated rotenone-induced cleaved caspase-3 activation, with all changes showing significant dose-dependent reductions relative to rotenone-only treated cells.

ELISA Assay

Cell Line: BV-2 cells
Concentration: 0, 0.1, 1, 10.0 μM
Incubation Time: 1 h (pretreatment); 24 h (LPS co-incubation)
Result: Significantly reduced LPS-induced TNF-α release in a dose-dependent manner.
Almost completely inhibited LPS-induced TNF-α generation at 10 μM.

Cell Viability Assay

Cell Line: BV-2 cells
Concentration: 0, 0.1, 1, 10.0 μM
Incubation Time: 1 h (BV-2 pretreatment); 24 h (BV-2 LPS incubation); 24 h (PC12 culture with conditioned medium)
Result: Significantly reduced PC12 cell death caused by LPS-conditioned BV-2 medium in a dose-dependent manner.
Increased PC12 cell viability.

Western Blot Analysis

Cell Line: BV-2 cells
Concentration: 0, 0.1, 1, 10.0 μM
Incubation Time: 1 h (pretreatment); 24 h (LPS co-incubation)
Result: Significantly inhibited LPS-induced iNOS protein expression in a dose-dependent manner.\nSignificantly inhibited LPS-induced p38 MAPK phosphorylation in a dose-dependent manner.
Showed no significant effect on phosphorylated JNK or ERK1/2 levels.
体内研究
(In Vivo)

Polygalasaponin F (50-200 mg/kg,p.o.,每日 1 次,5-7 天) 可通过减轻体重下降、提高存活率、降低肺部炎症反应与病毒载量、抑制促炎细胞因子和前列腺素的产生、以及抑制 NF-κB 和 Raf/MEK/ERK 通路蛋白的表达,保护小鼠免受甲型 H1N1 流感病毒诱导的肺炎损伤。
Polygalasaponin F (15-30 mg/kg,i.p.,每日 1 次,10 天) 可呈剂量依赖性缓解雄性 KM 小鼠的脑缺血再灌注损伤;其中 30 mg/kg 剂量较模型组可使脑梗死体积减少约 55%,同时能抑制神经元凋亡并阻断过度的线粒体自噬。

Animal Model: BALB/c (female, specific-pathogen-free, 6-8 weeks old, intranasal infection with influenza H1N1 virus)
Dosage: 50 mg/kg; 100 mg/kg; 200 mg/kg
Administration: p.o.; once daily; 5 days (starting 2 hours post-infection)
Result: Relieved clinical symptoms.
Reduced body weight loss.
Prolonged survival time.
Significantly lowered lung histopathology scores and lung index.
Inhibited influenza virus M gene expression in lung tissue.
Significantly reduced lung tissue levels of IL-1β, TNF-α, IL-4, IFN-γ, TXA2, and PGE2.
Significantly decreased the lung tissue expression of NF-κB p65, IκBα, and MEK1 proteins relative to the untreated infected control.\n
Resulted in higher survival rates.
Reduced body weight loss.
Significantly prolonged survival time compared to the untreated infected control group.
Animal Model: KM (male, 6 weeks old, 30-35 g, middle cerebral artery occlusion followed by reperfusion)
Dosage: 15 mg/kg; 30 mg/kg
Administration: i.p.; daily; 10 consecutive days (7 days pre-surgery, 3 days post-surgery)
Result: Reduced modified Neurological Severity Score (mNSS) relative to model group at 15 mg/kg and to a greater extent at 30 mg/kg.
Improved wire-hanging test performance (increased score and hanging time) and balance beam test performance (decreased score) relative to model group at 15 mg/kg and to a greater extent at 30 mg/kg.
Reduced cerebral infarct volume from ~33% to ~28% relative to model group at 15 mg/kg, and from ~33% to ~15% (a ~55% reduction) at 30 mg/kg.
Attenuated hippocampal neuronal damage (preserved cellular architecture, reduced vacuolation, maintained Nissl body integrity) relative to model group at 15 mg/kg and to a greater extent at 30 mg/kg.
Reduced TUNEL-positive cells in hippocampal CA1 (from ~70% to ~50%), CA3 (from ~70% to ~35%), and DG (from ~80% to ~35%) regions relative to model group at 15 mg/kg; reduced TUNEL-positive cells in hippocampal CA1 (from ~70% to ~20%), CA3 (from ~70% to ~10%), and DG (from ~80% to ~20%) regions relative to model group at 30 mg/kg.
Normalized Bax and Bcl-2 protein expression (reduced Bax/β-actin ratio, increased Bcl-2/β-actin ratio) relative to model group at 15 mg/kg and to a greater extent at 30 mg/kg.
Reduced LC3-TOM20 colocalization from ~80% to ~60% relative to model group at 15 mg/kg, and from ~80% to ~45% at 30 mg/kg.
Reduced LC3II/LC3I ratio, increased TOM20/β-actin ratio, and increased p62/β-actin ratio relative to model group at 15 mg/kg and to a greater extent at 30 mg/kg.
性状 固体
颜色 White to off-white

化学信息

分子量 1091.24
分子式 C53H86O23
CAS No. 882664-74-6
别名 瓜子金皂苷己

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.83 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (91.64 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM0.9164 mL4.5819 mL9.1639 mL22.9097 mL
5 mM0.1833 mL0.9164 mL1.8328 mL4.5819 mL
10 mM0.0916 mL0.4582 mL0.9164 mL2.2910 mL
15 mM0.0611 mL0.3055 mL0.6109 mL1.5273 mL
20 mM0.0458 mL0.2291 mL0.4582 mL1.1455 mL
25 mM0.0367 mL0.1833 mL0.3666 mL0.9164 mL
30 mM0.0305 mL0.1527 mL0.3055 mL0.7637 mL
40 mM0.0229 mL0.1145 mL0.2291 mL0.5727 mL
50 mM0.0183 mL0.0916 mL0.1833 mL0.4582 mL
60 mM0.0153 mL0.0764 mL0.1527 mL0.3818 mL
80 mM0.0115 mL0.0573 mL0.1145 mL0.2864 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

瓜子金皂苷己 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础